Showing 2451-2460 of 5268 results for "".
- Sciton Rolls Out BBLINK Goggles for Improved Eye Protectionhttps://practicaldermatology.com/news/sciton-rolls-out-bblink-goggles-for-improved-eye-protection/2460903/Sciton Inc. is launching BBLINK Goggles. These smart glasses physically blink for the user to block out strain inducing light flashes, leading to improved treatment visibility and a more pleasant experience for the practitioner. BBLINK Goggles feature proprietary technol
- Experts Call for Greater Attention to Persistent Redness of Rosaceahttps://practicaldermatology.com/news/experts-call-for-greater-attention-to-persistent-redness-of-rosacea/2460896/Dermatologists should place greater emphasis on persistent facial erythema of rosacea, a panel of experts concludes. Their recommendations, based on a National Rosacea Society (NRS) roundtable conversation, appear in the <
- European Commission Approves UCB's BIMZELX for Adults with Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/european-commission-approves-ucbs-bimzelx-for-adults-with-moderate-to-severe-plaque-psoriasis/2460895/The European Commission (EC) has granted marketing authorization for UCB's bimekizumab (Bimzelx) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Bimekizumab is the first approved treatment in the European Union (EU) for moderate
- Open-label Extension Study Shows Long-term Safety, Efficacy for UCB's Bimekizumab in PsOhttps://practicaldermatology.com/news/open-label-extension-study-shows-long-term-safety-efficacy-for-ucbs-bimekizumab-in-pso/2460883/New interim data from an open-label extension trial to assess the long-term safety, tolerability, and efficacy of bimekizumab show that the majority of patients who achieved complete or near complete skin clearance after 16 weeks of bimekizumab treatment maintained these responses through to
- Rinvoq Has Quicker Onset, Higher EASI Scores than Dupixent in Phase 3b Study of Adults with Atopic Dermatitishttps://practicaldermatology.com/news/rinvoq-bests-dupixent-in-phase-3b-study-of-adults-with-atopic-dermatitis/2460882/AbbVie’s JAK Inhibitor Rinvoq (upadacitinib) performed better than Dupixent (dupilumab) for primary and all ranked secondary endpoints in a phase 3b head-to-head study in adults with atopic dermatitis (AD), according to a
- Dr. Jennifer Schoch Wins NEA/PeDRA 2021 Childhood Eczema Challenge Granthttps://practicaldermatology.com/news/dr-jennifer-schoch-wins-neapedra-2021-childhood-eczema-challenge-grant/2460878/The National Eczema Association (NEA) and the
- Arcutis Enrolls First Patient in Phase 3 Trial of Roflumilast for SDhttps://practicaldermatology.com/news/arcutis-enrolls-first-patient-in-phase-3-trial-of-roflumilast-for-sd/2460860/The first patient has been enrolled in the pivotal Phase 3 clinical trial evaluating topical roflumilast foam (ARQ-154) as a potential treatment for seborrheic dermatitis. Arcutis Biotherapeutics, Inc. is develo
- Vivacare Launches Eczema Education Resources in Collaboration with Allergy & Asthma Networkhttps://practicaldermatology.com/news/vivacare-launches-eczema-education-resources-in-collaboration-with-allergy-asthma-network/2460855/Vivacare has introduced in-depth eczema education resources from the Allergy & Asthma Network. The program will provide helpful resources for more than 3,000 allergists, dermatologists and primary care providers to distribute to their patients. These printable handouts, videos and patient sup
- Level Ex Expands into Dermatology with Launch of Top Derm Medical Education Gamehttps://practicaldermatology.com/news/level-ex-expands-into-dermatology-with-launch-of-top-derm-medical-education-game/2460854/Level Ex, creator of medical video games for physicians, has expanded into the dermatology field with the launch of its newest medical mobile game, Top Derm. The company&rs
- European Commission Approves Libtayo as First Immunotherapy for Patients with Advanced BCChttps://practicaldermatology.com/news/european-commission-approves-libtayo-as-first-immunotherapy-for-patients-with-advanced-bcc/2460851/The PD-1 inhibitor Libtayo® (cemiplimab, Regeneron/Sanofi) is approved by the European Commission to treat adults with locally advanced or metastatic basal cell carcinoma (BCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI). Libtayo is now approved for thr